EP3184523
N-((4,6-dímetýl-2-oxó-L,2-díhýdrópýridín-3-ýl)metýl)-5-(etýl(tetrahýdró-2H-pýran-4-ýl)amínó)-4-metýl-4‘-(morfólínóme týl)-[L,1‘-bífenýl]-3-karboxamíð-vetnisbrómíð til notkunar við meðhöndlun á frumufjölgunarröskun í blóðkerfinu
:
EP einkaleyfi í gildi á Íslandi:
11.4.2013:
19.6.2019:
16191716.6
:
26.8.2019:
15.9.2019
:
10.4.2033:
10.4.2026:
30.4.2026
:
N-((4,6-DIMETHYL-2-OXO-L,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL (TETRAHYDRO-2H-PYRAN-4-YL)AMINO)-4-METHYL-4'-(MORPHOLINOMETHYL)-[L,1'-BIPHENYL]-3-CARBOXAMIDE HYDROBROMIDE FOR USE IN THE TREATMENT OF A CELL PROLIFERATIVE DISORDER OF THE HEMATOLOGIC SYSTEM
11.4.2013
19.6.2019
26.8.2019
15.9.2019
10.4.2026
:
Epizyme Inc:
400 Technology Square, 4th Floor, 02139, Cambridge, US
:
Eisai R&D Management Co., Ltd.:
6-10, Koishikawa-4-chome Bunkyo-ku, 112-8088, Tokyo, JP
:
KUNTZ, Kevin Wayne:
Woburn, MA Massachusetts, US
:
HUANG, Kuan-chun:
Andover, MA Massachusetts, US
:
CHOI, Hyeong Wook:
Andover,, US
:
SANDERS, Kristen:
Andover, MA Massachusetts, US
:
MATHIEU, Steven:
Andover, MA Massachusetts, US
:
CHANDA, Arani:
Andover, MA Massachusetts, US
:
FANG, Frank:
Andover, MA Massachusetts, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201261624215 P:
13.4.2012:
US
:
C07D 405/12, A61K 31/5377, A61P 35/00, A61P 35/02
: 8
: 18.3.2020
: 10.4.2021
: Sigurjónsson & Thor ehf.
: 9
: 18.3.2021
: 10.4.2022
: Sigurjónsson & Thor ehf.
: 10
: 21.3.2022
: 10.4.2023
: Patice ehf.
: 11
: 21.3.2023
: 10.4.2024
: Árnason Faktor ehf.
: 12
: 7.3.2024
: 10.4.2025
: Árnason Faktor ehf.
: 13
: 14.3.2025
: 10.4.2026
: Árnason Faktor ehf.